Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37708911

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Haematol
Publication date
2023 Oct
First author
Voorhees PM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2023 Oct;10(10):e788-e789. doi: 10.1016/S2352-3026(23)00244-2.
    note
    Source null
    related pmid
    37793762
    relationship
    Comment in

Authors and identifiers

  1. name
    Voorhees PM
    type
    Author
  2. name
    Sborov DW
    type
    Author
  3. name
    Laubach J
    type
    Author
  4. name
    Kaufman JL
    type
    Author
  5. name
    Reeves B
    type
    Author
  6. name
    Rodriguez C
    type
    Author
  7. name
    Chari A
    type
    Author
  8. name
    Silbermann R
    type
    Author
  9. name
    Costa LJ
    type
    Author
  10. name
    Anderson LD Jr
    type
    Author
  11. name
    Nathwani N
    type
    Author
  12. name
    Shah N
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Voorhees PM
    type
    Author
  2. name
    Sborov DW
    type
    Author
  3. name
    Laubach J
    type
    Author
  4. name
    Kaufman JL
    type
    Author
  5. name
    Reeves B
    type
    Author
  6. name
    Rodriguez C
    type
    Author
  7. name
    Chari A
    type
    Author
  8. name
    Silbermann R
    type
    Author
  9. name
    Costa LJ
    type
    Author
  10. name
    Anderson LD Jr
    type
    Author
  11. name
    Nathwani N
    type
    Author
  12. name
    Shah N
    type
    Author
bibliography ids
  1. nci-bib-e9a6f3aa9da7cd8560d113ee
book metadata
content sha256
610b11d18bf78e46eb33da777abe0bb64d3848fb232af811697db389d57c4d78
document type
citation
dois
  1. 10.1016/S2352-3026(23)00217-X
electronic publication date
display
2023 Sep 11
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:37708911
immutable id
pubmed:37708911@610b11d18bf78e46eb33da777abe0bb64d3848fb232af811697db389d57c4d78
journal
abbreviation
Lancet Haematol
issn electronic
2352-3026
issn print
Source null
issue
10
name
The Lancet. Haematology
nlm unique id
101643584
pages
e825-e837
volume
10
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2023 Oct;10(10):e788-e789. doi: 10.1016/S2352-3026(23)00244-2.
    note
    Source null
    related pmid
    37793762
    relationship
    Comment in
outcomes validated
false
pmid
37708911
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
cd05062857b84420a37b9a61ee4598b6d1ec1c60ad8a82b44b0853ba5a5ca99e
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Oct
precision
month
year
2023
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase II
  3. Journal Article
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37708911/
title
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

Preserved source evidence · Not medical advice